Valeo Pharma Inc
Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization … Read more
Valeo Pharma Inc (VPHIF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of July 2024: -0.007x
Based on the latest financial reports, Valeo Pharma Inc (VPHIF) has a cash flow conversion efficiency ratio of -0.007x as of July 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($451.00K) by net assets ($-63.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Valeo Pharma Inc - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how Valeo Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Valeo Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valeo Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DONGFENG MOTOR GP-H
MU:D4D
|
N/A |
|
Nam Mu Hydropower JSC
VN:HJS
|
N/A |
|
Petrolimex Information Technology and Telecommunication JSC
VN:PIA
|
N/A |
|
CFAGF
OTCGREY:CFAGF
|
0.018x |
|
Wells Fargo & Company PFD DIV EQUALIZ
PINK:WFCNP
|
0.023x |
|
Bioventix
LSE:BVXP
|
0.305x |
|
Rocca SA
WAR:RCA
|
-0.160x |
|
Entest Biomedical Inc
PINK:ETNI
|
0.337x |
Annual Cash Flow Conversion Efficiency for Valeo Pharma Inc (2016–2023)
The table below shows the annual cash flow conversion efficiency of Valeo Pharma Inc from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-10-31 | $-40.34 Million | $-15.70 Million | 0.389x | -75.64% |
| 2022-10-31 | $-17.85 Million | $-28.50 Million | 1.597x | +126.62% |
| 2021-10-31 | $2.05 Million | $-12.31 Million | -5.999x | -247.48% |
| 2020-10-31 | $3.07 Million | $-5.30 Million | -1.726x | -101.65% |
| 2019-10-31 | $-22.00K | $-2.31 Million | 104.864x | +10654.19% |
| 2018-10-31 | $-1.37 Million | $-1.33 Million | 0.975x | +106.06% |
| 2017-10-31 | $-2.60 Million | $-1.23 Million | 0.473x | +122.85% |
| 2016-10-31 | $955.75K | $-1.98 Million | -2.071x | -- |